20 completed, 3 recruiting, 3 unknown, 2 terminated. 12 Phase 4, 8 Phase 1, 4 Phase 2, 2 Not applicable, 2 Phase 3.
Follow Cefdinir: new trials by email Literature Review of Cefdinir trials Research Report on Cefdinir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge - Drug Allergy, Cephalosporin Allergy | Phase 2 | Recruiting | Massachusetts General Hospital | 300 | 2025-05-05 | 2026-09-04 |
| Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting Gentamicin, Standard of Care - Urinary Tract Infections | Phase 2 | Unknown | Mercy Health Ohio | 160 | 2022-10-01 | 2023-01-27 |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: - Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension | Recruiting | Duke University | 5000 | 2020-03-05 | 2026-08-21 | |
| The Effect of Chinese Herbal Medicine for Reducing the Application of Antibiotics in the Treatment of Acute Mastitis CHPM (Chinese Herbal Patent Medicine ), Antibiotics Cefdinir Capsules, Education - Mastitis Acute Female | Phase 2 / Phase 3 | Unknown | Beijing University of Chinese Medicine | 306 | 2018-12-20 | 2020-07-07 |
| Comparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Adults Cefdinir/clavulanic acide 300/125 mg film-coated tablets, Cefdinir 300Mg Capsule - Acute Exacerbation of Chronic Bronchitis, Community-Acquired Pneumoniae | Phase 4 | Unknown | Neutec Ar-Ge San ve Tic A.Ş | 50 | 2017-11-01 | 2018-01-17 |
| Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Placebo, Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole - Antibiotics, Pituitary Adenoma | Phase 4 | Recruiting | St. Joseph's Hospital and Medical Center, Phoenix | 116 | 2017-07-01 | 2018-08-15 |
| Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children Amoxicillin, Amoxicillin-clavulanate, Cefdinir - Pneumonia | Phase 4 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 385 | 2016-12-02 | 2021-02-03 |
| Safety and Efficacy of Cefecin Tab. in Patients With Acute Sinusitis Cefecin Tab., Omnicef Cap. - Acute Sinusitis | Phase 4 | Terminated | Korea United Pharm. Inc. | 284 | 2015-08-31 | 2020-12-11 |
| Patients Response to Early Switch To Oral:Osteomyelitis Study oral antibiotics, intravenous antibiotics - Osteomyelitis | Early Phase 1 | Terminated | Julio Ramirez | 11 | 2014-03-06 | 2021-04-06 |
| Comparing Healthcare Utilization Between Adenotonsillectomy Patients With and Without Postoperative Antibiotic Use Antibiotic - Snoring, Strep Throat | Not applicable | Completed | University of Missouri-Columbia | 58 | 2012-03-01 | 2017-01-19 |
| Effectiveness of Oral Antibiotics in the Treatment of Severe Acute Malnutrition Placebo, Amoxicillin, Cefdinir - Kwashiorkor, Marasmus | Not applicable | Completed | Washington University School of Medicine | 2767 | 2009-12-01 | 2026-08-17 |
| Cefdinir Capsules 300 mg, Fasting Cefdinir Capsules 300 mg, OMNICEF® 300 mg - Healthy | Phase 1 | Completed | Teva Pharmaceuticals USA | 32 | 2005-07-01 | 2024-08-20 |
| Cefdinir Capsules 300 mg, Non-fasting Cefdinir Capsules 300 mg, OMNICEF® Capsule 300 mg - Healthy | Phase 1 | Completed | Teva Pharmaceuticals USA | 32 | 2005-07-01 | 2024-08-20 |
| To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250 mg/5 ml Oral Suspension Fed Conditions Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria), Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA) - Healthy | Phase 1 | Completed | Sandoz | 40 | 2005-04-01 | 2017-03-29 |
| To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicef 300 mg Capsule Fasting Conditions Cefdinir 300 mg Capsule (Sandoz, Austria), Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA) - Healthy | Phase 1 | Completed | Sandoz | 28 | 2005-04-01 | 2017-03-29 |
| To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 300 mg Capsule Fed Conditions Cefdinir 300 mg Capsule (Sandoz, Austria), Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA) - Healthy | Phase 1 | Completed | Sandoz | 28 | 2005-04-01 | 2017-03-29 |
| To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250mg/5 ml Oral Suspension Fasting Conditions Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria), Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA) - Healthy | Phase 1 | Completed | Sandoz | 40 | 2005-04-01 | 2017-03-29 |
| Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting Cefdinir for oral suspension 250 mg/5mL, OMNICEF® for oral suspension 250 mg/5mL - Healthy | Phase 1 | Completed | Teva Pharmaceuticals USA | 32 | 2005-03-01 | 2024-08-20 |
| A Study to Compare Cefdinir and Cephalexin for the Treatment of Mild to Moderate Uncomplicated Skin Infections cefdinir, cephalexin - Mild to Moderate Uncomplicated Skin and Skin Structure Infections | Phase 4 | Completed | Abbott | 380 | 2005-03-01 | 2007-10-25 |
| Cefdinir for Oral Suspension 250 mg/5mL, Fasting Cefdinir for oral suspension 250 mg/5mL, OMNICEF® for oral suspension 250 mg/5mL - Healthy | Phase 1 | Completed | Teva Pharmaceuticals USA | 32 | 2005-02-01 | 2024-08-20 |
Showing 20 of 28. Sign in to see all of them.
Otitis Media (3) · Cellulitis (2) · Pneumonia (2) · Adrenal Insufficiency (1) · Anaphylaxis (1) · Arrhythmias, Cardiac (1) · Attention Deficit Disorder with Hyperactivity (1) · Breast Feeding (1) · Bronchopulmonary Dysplasia (1) · COVID-19 (1) · Coronavirus Infections (1) · Down Syndrome (1) · Drug Hypersensitivity (1) · Edema (1) · Heart Failure (1)
Abbott (8) · Sandoz (4) · Teva Pharmaceuticals USA (4) · Beijing University of Chinese Medicine (1) · Duke University (1) · Julio Ramirez (1) · Korea United Pharm. Inc. (1) · Massachusetts General Hospital (1) · Mercy Health Ohio (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Neutec Ar-Ge San ve Tic A.Ş (1) · St. Joseph's Hospital and Medical Center, Phoenix (1) · University of Chicago (1) · University of Missouri-Columbia (1) · Washington University School of Medicine (1)
United States (19) · Canada (1) · Chile (1) · China (1) · Costa Rica (1) · Dominican Republic (1) · Guatemala (1) · Israel (1) · Malawi (1) · Panama (1) · Poland (1) · Turkey (Türkiye) (1)
Richard Larouche, M.D. (3) · Soran Hong, M.D. (2) · Andrew Little, MD (1) · Benoit Girard, M.D. (1) · Chi Hornik (1) · David A Khan, MD (1) · David Seligson, MD (1) · Eliav Gov-Arie, MD (1) · Jacquelynne Corey, M.D. (1) · James D. Carlson, M.D. (1) · James D. Carlson, Pharm. D. (1) · James Evans, MD (1) · Julio Ramirez, MD (1) · Kimberly G Blumenthal, MD, MSc (1)
PMID 15276398, PMID 15840453, PMID 19588358, PMID 22530208, PMID 23363496, PMID 27895846, PMID 35040920, PMID 35323040, PMID 38029215, PMID 4902833, PMID 8948280
U01AI184071 (1)